English
Español
Français
Kreyòl ayisyen
Polski
Português
Russkij
العربية
አማርኛ
中文
한국어

Navigation

eResources Library Contacts My Library

Information skills training

Training calendar

FAQs

Request Evidence Search

Summaries of Evidence

LENUS Institutional Repository

Keeping up to date

Sign in for full access

Library Home Page

Library Hours & Location

eResources by Category

Suggestions and feedback

Languages

English

Kreyòl ayisyen

Look for

Main Navigation

Filter Results

Narrow Your Results

Available Now At

Connolly Hospital Dublin

St. Luke’s Radiation Oncology Network Dublin (1)

Author

Crown, John (1)

Publication Date

Publication Date from

Publication Date to

Published in the last
year • 5 years • 10 years

Subject

BACKGROUND: No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC. We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines. MATERIALS AND METHODS: EGFR and phosphorylated EGFR were measured by enzyme-linked immunosorbent assay. Sensitivity to EGFR inhibitors alone and in combination with chemotherapy was assessed. Effects of gefitinib on EGFR signalling and cell cycle were also examined. RESULTS: EGFR was overexpressed in the TNBC compared with the human epidermal growth factor receptor 2 (HER-2)-positive cell lines. Phosphorylation of EGFR was detected in the TNBC cells in response to epidermal growth factor stimulation and was blocked by gefitinib treatment. However, the TNBC cell lines were less sensitive to EGFR inhibition than the HER-2-positive cell lines. Response to gefitinib was associated with reduced phosphorylation of both mitogen activated protein kinase (MAPK) and Akt and induction of G(1) arrest. Gefitinib enhanced response to both carboplatin and docetaxel in the TNBC cells, and the triple combination of gefitinib, carboplatin and docetaxel was synergistic. CONCLUSIONS: Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy. Gefitinib combined with carboplatin and docetaxel warrants further investigation in TNBC (1)

Item Type

Print Book (1)

Rating

(0)

(0)

Three Star & Up

(0)

(0)

(0)

Browse
» Bill Corkery
» Showing 1 - 1 of 1

Bill Corkery

Sort by

Hide Covers

Covers List

Save Search
Email this Search
Get RSS Feed

Epidermal_growth_factor_receptor_as_a_potential_therapeutic_target_in_triple-negative_breast_cancer

1) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

Author

Pub. Date

2009

Print Material
Show Edition

On Shelf

1 copies available.

SEE ALL LOCATIONS

See Full Copy Details

SHARE

Powered By Aspen Discovery supported by Interleaf Technologies & Open Fifth [PTFS-Europe]
v. 25.03.00

CONNECT WITH US

Loading, please wait

...